SCHEMBL4094159

SCHEMBL4094159

O=C1CCCN1CCOc1ccc2cc(Br)ccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.57
PDK2 Q15119 5/20 0.50
KMT2A Q03164 4/20 0.48
MEN1 O00255 2/20 0.48
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAOB P27338 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
ATM Q13315 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A4 P31645 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4090609 0.79 MAOB (0.42) POLBNPSR1TDP1MAOBNPC1
SCHEMBL4089595 0.79 PDK2 (0.50) PDK2NPSR1TDP1MAOBNPC1
SCHEMBL23640332 0.78 POLB (0.60) POLBPDK2KMT2AMEN1CCNC
SCHEMBL1640980 0.77 LTA4H (0.68) POLBNPSR1MAOBATML3MBTL1
SCHEMBL15716363 0.76 POLB (0.48) POLBPDK2KMT2AMEN1CCNC
SCHEMBL13106477 0.76 POLB (0.67) POLBPDK2KMT2AMEN1MTNR1A
SCHEMBL1620283 0.76 MEN1 (0.52) POLBPDK2KMT2AMEN1CCNC
SCHEMBL2229518 0.76 POLB (0.56) POLBPDK2KMT2AMEN1CCNC
SCHEMBL22434503 0.76 POLB (0.60) POLBPDK2KMT2AMEN1CCNC
SCHEMBL20163507 0.76 POLB (0.56) POLBPDK2KMT2AMEN1CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2065383-A1 Indazole compounds and methods of use thereof as protein kinase inhibitors Signal Pharmaceuticals, Inc. (US) 2009-06-03 EP disclosed
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF BHAGWAT SHRIPAD S 2009-04-16 US disclosed
EP-1692128-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS Signal Pharmaceuticals LLC (US) 2006-08-23 EP disclosed
US-20060004043-A1 Indazole compounds and methods of use thereof BHAGWAT SHRIPAD S 2006-01-05 US disclosed
WO-2005051942-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS SIGNAL PHARMACEUTICALS, LLC (US) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099178-A1 INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF WNT3, WNT3A, WNK3 POLB 3400/4885PDK2 412/4885KMT2A 4034/4885
US-20060004043-A1 Indazole compounds and methods of use thereof WNT3, WNT3A, WNK3 POLB 3558/4885PDK2 386/4885KMT2A 4112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.